Journal: Scientific reports
This retrospective study evaluated the impact of local consolidative therapy (LCT) on survival in 127 metastatic non-small cell lung cancer (mNSCLC) patients with oligoresidual disease (ORD) after first-line PD-1/PD-L1 inhibitor treatment, excluding those with EGFR/ALK alterations.
Patients receiving LCT (surgery, SABR, MWA, cryoablation, or SABT; n=57) showed significantly improved survival outcomes compared to those on systemic therapy alone (n=70):
- Median progression-free survival: 14.0 vs. 7.0 months
- Overall survival: 27.3 vs. 15.8 months
These survival benefits persisted regardless of PD-L1 expression levels.
Multivariate analysis identified both LCT and high PD-L1 expression as independent favorable prognostic factors.
Grade 3-4 adverse events related to LCT were noted in 8.8% of patients.
Overall, the findings support incorporating LCT into treatment strategies for mNSCLC patients with ORD following immunotherapy.